MedWatch

Why has the Novo-share been skyrocketing in the last couple of days?

That‘s the question posed – and answered – by Danish bank Nordea in a new memo. The unanimous advice of stock market analysts is not to sell.

Foto: Thomas Picard / Stock.Xchng

The pharmaceutical flagship Novo Nordisk has rarely been creating as much buzz as it is at the moment. The stock market is alive with enthusiasm, and it is mainly the candidate drug against obesity that is the talk of the town.

The Novo-share has gone up about 25 % since the turn of the year, and Danish newspaper Berlingske reveals that only 1 out of 23 Novo-analysts recommend to sell. 11 say buy and 11 say hold.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier